GB201504432D0 - Materials and methods for diagnosis and treatment of alzheimers disease - Google Patents

Materials and methods for diagnosis and treatment of alzheimers disease

Info

Publication number
GB201504432D0
GB201504432D0 GB201504432A GB201504432A GB201504432D0 GB 201504432 D0 GB201504432 D0 GB 201504432D0 GB 201504432 A GB201504432 A GB 201504432A GB 201504432 A GB201504432 A GB 201504432A GB 201504432 D0 GB201504432 D0 GB 201504432D0
Authority
GB
United Kingdom
Prior art keywords
diagnosis
treatment
materials
methods
alzheimers disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201504432A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Priority to GB201504432A priority Critical patent/GB201504432D0/en
Publication of GB201504432D0 publication Critical patent/GB201504432D0/en
Priority to JP2017549301A priority patent/JP6954839B2/ja
Priority to CA2979773A priority patent/CA2979773A1/en
Priority to EP16714282.7A priority patent/EP3271728B1/en
Priority to US15/559,371 priority patent/US10718785B2/en
Priority to PCT/EP2016/055883 priority patent/WO2016146783A1/en
Priority to JP2021102858A priority patent/JP2021177180A/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y504/00—Intramolecular transferases (5.4)
    • C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
    • C12Y504/02002—Phosphoglucomutase (5.4.2.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
GB201504432A 2015-03-17 2015-03-17 Materials and methods for diagnosis and treatment of alzheimers disease Ceased GB201504432D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB201504432A GB201504432D0 (en) 2015-03-17 2015-03-17 Materials and methods for diagnosis and treatment of alzheimers disease
JP2017549301A JP6954839B2 (ja) 2015-03-17 2016-03-17 アルツハイマー病の診断及び治療のための材料及び方法
CA2979773A CA2979773A1 (en) 2015-03-17 2016-03-17 Materials and methods for diagnosis and treatment of alzheimer's disease
EP16714282.7A EP3271728B1 (en) 2015-03-17 2016-03-17 Materials and methods for diagnosis and treatment of alzheimer's disease
US15/559,371 US10718785B2 (en) 2015-03-17 2016-03-17 Materials and methods for diagnosis and treatment of Alzheimer's disease
PCT/EP2016/055883 WO2016146783A1 (en) 2015-03-17 2016-03-17 Materials and methods for diagnosis and treatment of alzheimer's disease
JP2021102858A JP2021177180A (ja) 2015-03-17 2021-06-22 アルツハイマー病の診断及び治療のための材料及び方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201504432A GB201504432D0 (en) 2015-03-17 2015-03-17 Materials and methods for diagnosis and treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
GB201504432D0 true GB201504432D0 (en) 2015-04-29

Family

ID=53016214

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201504432A Ceased GB201504432D0 (en) 2015-03-17 2015-03-17 Materials and methods for diagnosis and treatment of alzheimers disease

Country Status (6)

Country Link
US (1) US10718785B2 (enExample)
EP (1) EP3271728B1 (enExample)
JP (2) JP6954839B2 (enExample)
CA (1) CA2979773A1 (enExample)
GB (1) GB201504432D0 (enExample)
WO (1) WO2016146783A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509134D0 (en) 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
KR102034929B1 (ko) * 2017-09-27 2019-10-22 한양대학교 산학협력단 Nckap1 단백질 또는 상기 단백질을 암호화하는 유전자를 포함하는 신경계 퇴행성질환의 예방 또는 치료용 약학적 조성물
KR102063610B1 (ko) * 2018-05-23 2020-01-08 충북대학교 산학협력단 퇴행성 신경질환 진단용 신규한 바이오마커 및 이의 용도
KR102232200B1 (ko) * 2019-03-13 2021-03-25 아주대학교산학협력단 알츠하이머치매 진단 바이오마커
US20220003787A1 (en) * 2018-10-30 2022-01-06 Ajou University Industry-Academic Cooperation Foundation Biomarker proteins for diagnosing alzheimer's dementia and use thereof
KR101992060B1 (ko) * 2018-10-30 2019-06-21 아주대학교산학협력단 알츠하이머치매 진단 체액 바이오마커 후보 단백4종
CN109738653B (zh) * 2019-01-11 2022-04-12 湖南诺琪生物科技有限公司 用于阿尔茨海默症的检测、诊断或风险预测的抗原蛋白组合以及包含其的试剂盒
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN110261272B (zh) * 2019-07-05 2020-08-18 西南交通大学 基于地理探测和pca对pm2.5浓度分布的关键影响因子筛选方法
CN112336859A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法
KR20220104706A (ko) * 2019-10-28 2022-07-26 에전 알츠하이머병의 침묵 단계를 진단하기 위한 바이오마커 및 이의 용도
KR102313455B1 (ko) * 2020-02-27 2021-10-15 이화여자대학교 산학협력단 알츠하이머병 경도인지장애의 진단 또는 알츠하이머병 치매로의 진행 위험성 예측 방법
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN112695084A (zh) * 2021-02-08 2021-04-23 山东大学第二医院 诊断阿尔茨海默病和阿尔茨海默病进展的生物标志物及应用
GB202102399D0 (en) * 2021-02-19 2021-04-07 Univ Manchester Methods of determining alzheimer's disease
US20250270618A1 (en) * 2021-03-08 2025-08-28 The Children's Medical Center Corporation Methods for diagnosis and treatment of alzheimer's disease
US20230144446A1 (en) * 2021-07-23 2023-05-11 Cassava Sciences, Inc. Blood-based diagnostic assays for alzheimer's disease
WO2023235871A2 (en) * 2022-06-03 2023-12-07 Seer, Inc. Systems, compositions, and methods relating to neurodegenerative diseases
WO2024073067A2 (en) * 2022-09-30 2024-04-04 Mayo Foundation For Medical Education And Research Assessing and treating tremor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPWO2004001865A1 (ja) 2002-06-19 2005-10-27 株式会社東芝 熱電素子とそれを用いた電子部品モジュールおよび携帯用電子機器
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2005019825A2 (en) * 2003-08-20 2005-03-03 Genova Ltd. Secreted polypeptide species and use thereof
US7794948B2 (en) * 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2006110621A2 (en) * 2005-04-11 2006-10-19 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject
ES2453106T3 (es) * 2009-01-26 2014-04-04 Electrophoretics Limited Métodos de diagnóstico y pronóstico en relación con la enfermedad de Alzheimer
WO2010111587A1 (en) 2009-03-26 2010-09-30 Trustees Of The University Of Pennsylvania Modulators of tdp-43 mediated toxicity
WO2011005893A2 (en) * 2009-07-07 2011-01-13 Abbott Laboratories Biomarkers and methods for detecting alzheimer's disease
EP2553466A4 (en) 2010-04-01 2013-10-16 Banyan Biomarkers Inc MARKERS AND ASSAYS FOR DETECTING NEUROTOXICITY
WO2013086429A2 (en) * 2011-12-09 2013-06-13 Veracyte, Inc. Methods and compositions for classification of samples
GB2511525A (en) * 2013-03-05 2014-09-10 Randox Teoranta Methods and Compositions for the Diagnosis of Alzheimer's Disease
GB201310203D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease

Also Published As

Publication number Publication date
US10718785B2 (en) 2020-07-21
WO2016146783A1 (en) 2016-09-22
JP2018510343A (ja) 2018-04-12
US20180067133A1 (en) 2018-03-08
JP2021177180A (ja) 2021-11-11
CA2979773A1 (en) 2016-09-22
JP6954839B2 (ja) 2021-10-27
EP3271728B1 (en) 2024-02-28
EP3271728A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
GB201504432D0 (en) Materials and methods for diagnosis and treatment of alzheimers disease
IL258810A (en) Materials and methods for treating glycogen storage disease type 1a
IL256685B (en) An isolated tau-binding antibody and its use in the treatment and diagnosis of tauopathy
IL290994A (en) Methods of diagnosing and treating conduct disorder
IL246917B (en) Biomarker and early diagnosis methods for Alzheimer's disease
SG11201706766WA (en) Materials and methods for treatment of hemoglobinopathies
IL253945B (en) kdm1a inhibitors to treat the disease
PT3212233T (pt) Terapia combinada para o tratamento de doenças
AP2016009549A0 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
GB201413357D0 (en) Antibodies for treatment and diagnosis
ZA201800037B (en) Diagnosis and treatment of infectious disease
SG11201703704PA (en) Diagnosis and treatment of incipient diabetes
IL256103B (en) Compositions and methods for treating celiac sprue disease
GB201500875D0 (en) Antibodies for treatment and diagnosis
EP3137907A4 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
IL248210A0 (en) Methods and compositions for the treatment of vascular malformation
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
IL252904A0 (en) Methods and factors for treating diseases
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
EP3102940A4 (en) Anti-metalloprotease antibody for diagnosis and treatment of cancers
LT3137093T (lt) Alzheimerio ligos (ad) gydymas ir prevencija
IL248847A0 (en) Dosertalin dosage and method for treating adhd
IL246608A0 (en) Preparations and methods for treating heart disease
GB201401806D0 (en) Novel methods for diagnosis and therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)